Robert G Gish Consultants

09/17/2025

🩺 FREE Webinar: Understanding Wilson Disease 🍃

Join me on Wednesday, November 19, 2025 at 5:30 PM PST for a special LIVER Q & A Webinar presented by the Liver Coalition of San Diego. We’ll be diving into Wilson Disease—what it is, how it’s diagnosed, treatment options, and what life looks like living with it.

Whether you are someone affected by Wilson Disease, a caregiver, a healthcare professional — or you just want to learn more — this is a great opportunity to ask questions and gain a deeper understanding

🔗 Register here: https://livercoalition.org/events/liver-q-a/

Please share this with friends, family, or support groups who might benefit!

09/17/2025

People with Wilson disease cannot release copper from the liver at a normal rate. This genetic condition can cause life-threatening organ damage if left untreated. Learn more at our upcoming webinar, where Dr. Robert G Gish will provide an overview of Wilson disease. Register at https://livercoalition.zoom.us/webinar/register/WN_Cg_u0k5kQPWVsUDEu_PKHw #/registration

09/12/2025

🚨 Only 2 weeks left to submit abstracts for HEP-DART 2025!
Deadline: September 29, 2025

Join leading researchers and clinicians in Honolulu, Hawaii, and share your latest work in hepatitis research, treatment, and global health. See you there!

👉 Submit here: https://informedhorizonseducation.com/abstracts-hepdart-2025

09/12/2025

https://www.hcplive.com/view/intercept-voluntarily-withdrawals-obeticholic-acid-ocaliva-for-pbc-from-us-market

Intercept Pharmaceuticals has voluntarily withdrawn obeticholic acid from the US market following a request from the FDA.

09/10/2025

🌍💛 Did you know that preventing mother-to-child transmission of hepatitis B is one of the most important steps toward eliminating HBV worldwide?

Join me on September 16 for this important AASLD webinar: “Mother to Child Transmission of HBV” to learn about strategies, challenges, and solutions to protect the next generation

📅 Don’t miss it – register today:
https://liverlearning.aasld.org/URL/MothertoChild

Let’s work together to create an HBV-free future! ✨

09/09/2025

🌟 Exciting news! 🌟
I’ll be walking in the San Diego Liver Walk this year, and I’d love for you to join my team with American Pacific Health Foundation 💚

This event is all about raising awareness and support for liver health, research, and the patients and families affected. Together, we can make a difference while enjoying a fun and meaningful day out.

👉 Click here to join our team (or donate if you can’t attend):
https://runsignup.com/RaceGroups/189349/Groups/1887074

Let’s walk together, spread hope, and support an important cause 💪👟💚

08/26/2025

08/20/2025

🔜Join me on September 16 for this upcoming AASLD webinar! 🩺

Register for “Mother-To-Child Transmission of HBV” online now at https://www.aasld.org/webinar-mother-child-transmission-hbv

08/18/2025

An important read:
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00163-3/fulltext

We have learned from past experience: that when patients “don't meet guidelines” for treatment, the dropout rate from follow-up care is huge!

Also, specialty care is limited globally so:

Why do we propose to treat all patient with HBV who are HBV DNA+?
• HBV DNA+ correlates with risk:
– (risk of HCC, cirrhosis, LT and death)
Treatment decrease risk: 70% less HCC
90%+ decrease risk of cirrhosis and liver transplant
• Decrease Risk of Transmission U=U
– treatment to prevent infection
• Reduce Stigma
• Improve QOL
• Reduce HBV related extrahepatic disease
• Decrease other HBV related cancers (bile duct cancer is an example)
• Reduce Discrimination
• Partner with Patients who request treatment
• Meet WHO guidelines
• Keep HBV patients in care

Considerable attrition was seen across the chronic hepatitis B care cascade, with low rates of retention especially in patients not on antiviral therapy. Assessment for treatment eligibility and initiation of antiviral therapy were lower in primary versus hospital-based specialist care models. Chron...

08/08/2025

Hepatitis D Reclassified as Carcinogenic, According to WHO – Pharmacy Times
https://www.pharmacytimes.com/view/hepatitis-d-reclassified-as-carcinogenic-according-to-who
"The WHO’s announcement stems from the International Agency for Research on Cancer’s (IARC) reclassification of hepatitis D as carcinogenic, supported by data from a study published in The Lancet Oncology. All types of hepatitis are associated with acute liver infection; however, only hepatitis B, C, and D can lead to chronic infections with a higher risk of liver cirrhosis, failure, or cancer. According to the authors of the study’s findings, hepatitis D is associated with a 2- to 6-fold higher risk of liver cancer compared with hepatitis B."

WHO reclassifies hepatitis D as carcinogenic, urging global action to combat viral hepatitis and reduce liver cancer risk.

07/28/2025

🌍 Today is the day — World Hepatitis Day! 💉💪

Hepatitis B doesn’t just affect the liver — it can lead to liver cancer if left untreated. But there's something simple we can all do: get vaccinated. 🛡️

📢 Let's break it down:
✅ Hepatitis B is preventable.
✅ The vaccine is safe and effective.
✅ It also protects against liver cancer.

Spread the word, protect yourself, protect your community.
👉 Learn more: worldhepatitisday.org

07/25/2025

🩺More articles that support our goal of hepatitis elimination!👏

Why do we propose to treat all patient with HBV who are HBV DNA+?
• HBV DNA+ correlates with risk:
– (risk of HCC, cirrhosis, LT and death)
Treatment decrease risk: 70% less HCC
90%+ decrease risk of cirrhosis and liver transplant

• Decrease Risk of Transmission U=U
– treatment to prevent infection
• Reduce Stigma
• Improve QOL
• Reduce HBV related extrahepatic disease
• Decrease other HBV related cancers (bile duct cancer is an example)
• Reduce Discrimination
• Partner with Patients who request treatment
• Help with WHO elimination goals

Read both important articles at the links below👇

Scientific and medical evidence informing expansion of hepatitis B treatment guidelines https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00053-6/fulltext

Patient and public health perspectives to inform expansion of hepatitis B treatment guidelines https://authors.elsevier.com/a/1lUF78nByrGVzC

Chronic hepatitis B treatment relies on nucleoside or nucleotide analogue drugs that suppress hepatitis B virus (HBV) replication, normalise liver enzymes, and slow disease progression with excellent safety profiles. Treatment is not curative, and patients remain at risk of cirrhosis and hepatocellu...